Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
17,036
Total Claims
$1.8M
Drug Cost
979
Beneficiaries
$1,855
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+31%
Cost per patient vs peers
$1,855 vs $1,411 avg
+29%
Brand preference vs peers
13.8% vs 10.6% avg
Brand vs Generic
Brand: 2,315 claims · $1.5M
Generic: 14,518 claims · $272K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 173 | $199K |
| Apixaban | 153 | $161K |
| Rivaroxaban | 75 | $102K |
| Tirzepatide | 69 | $85K |
| Insulin Glargine,hum.Rec.Anlog | 102 | $74K |
| Empagliflozin | 39 | $71K |
| Insulin Glargine,hum.Rec.Anlog | 60 | $67K |
| Sitagliptin Phosphate | 48 | $61K |
| Insulin Aspart | 57 | $61K |
| Semaglutide | 57 | $58K |
| Sitagliptin Phos/Metformin Hcl | 26 | $35K |
| Dapaglifloz Propaned/Metformin | 22 | $33K |
| Fluticasone/Vilanterol | 57 | $33K |
| Dulaglutide | 32 | $32K |
| Icosapent Ethyl | 28 | $24K |
Prescribing Profile
Patient Profile
72
Avg Age
50%
Female
1.49
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data